{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:43:58Z","timestamp":1753890238318,"version":"3.41.2"},"reference-count":23,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,9]]},"DOI":"10.31744\/einstein_journal\/2022ao0067","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T19:11:22Z","timestamp":1668193882000},"source":"Crossref","is-referenced-by-count":3,"title":["Post-vaccination incidence and side effects of COVID-19 in a cohort of Brazilian healthcare professionals: an internet-based survey"],"prefix":"10.31744","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6643-1207","authenticated-orcid":false,"given":"Matheus","family":"Ballestero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3086-9623","authenticated-orcid":false,"given":"Renato Lucas Passos de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0603-3685","authenticated-orcid":false,"given":"Thiago Mamoru","family":"Sakae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-9998","authenticated-orcid":false,"given":"Luiz Guilherme Villares da","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-1179","authenticated-orcid":false,"given":"Luciano","family":"Furlanetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-5553","authenticated-orcid":false,"given":"Ricardo Santos de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"key":"key20221111141118_B1","doi-asserted-by":"crossref","first-page":"101619","DOI":"10.1016\/j.tmaid.2020.101619","article-title":"Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19","volume":"34","author":"Qu","year":"2020","unstructured":"Qu YM, Kang EM, Cong HY. Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19. Travel Med Infect Dis. 2020;34:101619.","journal-title":"Travel Med Infect Dis"},{"issue":"5","key":"key20221111141118_B2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","unstructured":"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-4. Erratum in: Lancet Infect Dis. 2020;20(9):e215.","journal-title":"Lancet Infect Dis"},{"key":"key20221111141118_B3","volume-title":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)","author":"Johns Hopkins University & Medicine","year":"2022","unstructured":"Johns Hopkins University & Medicine. Coronavirus Resource Center. Global Map. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Baltimore: JHU; 2022 [cited 2022 Jan 3]. Available from: https:\/\/coronavirus.jhu.edu\/map.html"},{"key":"key20221111141118_B4","doi-asserted-by":"crossref","first-page":"m4759","DOI":"10.1136\/bmj.m4759","article-title":"Vaccinating the UK: how the covid vaccine was approved, and other questions answered","volume":"371","author":"Mahase","year":"2020","unstructured":"Mahase E. Vaccinating the UK: how the covid vaccine was approved, and other questions answered. BMJ. 2020;371:m4759.","journal-title":"BMJ"},{"key":"key20221111141118_B5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.coi.2021.07.003","article-title":"COVID-19 vaccines","volume":"71","author":"Ndwandwe","year":"2021","unstructured":"Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021; 71:111-6. Review.","journal-title":"Curr Opin Immunol"},{"key":"key20221111141118_B6","volume-title":"Vacinas - Covid-19","author":"Brasil. Minist\u00e9rio da Sa\u00fade","year":"2022","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Vacinas - Covid-19. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; ANVISA; 2022 [citado 2022 Jan 4]. Dispon\u00edvel em: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/paf\/coronavirus\/vacinas"},{"issue":"2","key":"key20221111141118_B7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","unstructured":"McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463-72. Review.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"key20221111141118_B8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.15441\/ceem.21.067","article-title":"Adverse events and preventive measures related to COVID-19 vaccines","volume":"8","author":"Ahn","year":"2021","unstructured":"Ahn TK, Kang S, Paik JH, Seo YH. Adverse events and preventive measures related to COVID-19 vaccines. Clin Exp Emerg Med. 2021;8(3):153-9.","journal-title":"Clin Exp Emerg Med"},{"issue":"3","key":"key20221111141118_B9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/bcp.15024","article-title":"Numbers of spontaneous reports: how to use and interpret?","volume":"88","author":"Kant","year":"2022","unstructured":"Kant A, van Hunsel F, van Puijenbroek E. Numbers of spontaneous reports: how to use and interpret? Br J Clin Pharmacol. 2022;88(3):1365-8.","journal-title":"Br J Clin Pharmacol"},{"key":"key20221111141118_B10","volume-title":"Ten threats to global health in 2019","author":"World Health Organization (WHO)","year":"2022","unstructured":"World Health Organization (WHO). Ten threats to global health in 2019. Geneva: WHO; 2022 [cited 2022 Jan 4]. Available from: https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019"},{"key":"key20221111141118_B11","volume-title":"Coronavirus disease (COVID-19) pandemic","author":"World Health Organization (WHO)","year":"2022","unstructured":"World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. Geneva: WHO; 2022 [cited 2022 Jan 3]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019"},{"key":"key20221111141118_B12","volume-title":"Coronavirus disease 2019 (COVID-19)","author":"U.S. Food & Drug Administration (FDA)","year":"2022","unstructured":"U.S. Food & Drug Administration (FDA). Coronavirus disease 2019 (COVID-19). Silver Spring: FDA; 2022 [cited 2022 Jan 3]. Available from: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/counterterrorism-and-emerging-threats\/coronavirus-disease-2019-covid-19"},{"issue":"5","key":"key20221111141118_B13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/vaccines9050467","article-title":"Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials","volume":"9","author":"Pormohammad","year":"2021","unstructured":"Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021;9(5):467. Review.","journal-title":"Vaccines (Basel)"},{"issue":"6518","key":"key20221111141118_B14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.abe5938","article-title":"Understanding COVID-19 vaccine efficacy","volume":"370","author":"Lipsitch","year":"2020","unstructured":"Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science. 2020;370(6518):763-5.","journal-title":"Science"},{"key":"key20221111141118_B15","volume-title":"The Sinovac-CoronaVac COVID-19 vaccine: what you need to know","author":"World Health Organization (WHO)","year":"2022","unstructured":"World Health Organization (WHO). The Sinovac-CoronaVac COVID-19 vaccine: what you need to know. Geneva: WHO; 2022 [cited 2022 Jan 8]. Available from: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-sinovac-covid-19-vaccine-what-you-need-to-know"},{"issue":"27","key":"key20221111141118_B16","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, T\u00fcreci \u00d6, Nell H, Schaefer A, \u00dcnal S, Tresnan DB, Mather S, Dormitzer PR, \u015eahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20221111141118_B17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.","journal-title":"N Engl J Med"},{"issue":"10269","key":"key20221111141118_B18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","unstructured":"Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJ, Emary KR, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SH, Izu A, Jackson S, Jenkin D, Joe CC, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AV, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O\u2019Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, T\u00f6r\u00f6k ME, Toshner M, Turner DP, Vekemans J, Villafana TL, Watson ME, Williams CJ, Douglas AD, Hill AV, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. Erratum in: Lancet. 2021;397(10269):98.","journal-title":"Lancet"},{"issue":"10275","key":"key20221111141118_B19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81. Erratum in: Lancet. 2021;397(10275):670.","journal-title":"Lancet"},{"issue":"7","key":"key20221111141118_B20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"Menni","year":"2021","unstructured":"Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-49.","journal-title":"Lancet Infect Dis"},{"key":"key20221111141118_B21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2147\/IJGM.S310497","article-title":"Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study","volume":"14","author":"El-Shitany","year":"2021","unstructured":"El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study. Int J Gen Med. 2021;14:1389-401.","journal-title":"Int J Gen Med"},{"issue":"3","key":"key20221111141118_B22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3233\/WOR-210473","article-title":"Determining the frequency of serious adverse reactions of inactive SARS-COV-2 vaccine","volume":"69","author":"Kaya","year":"2021","unstructured":"Kaya F, Pirincci E. Determining the frequency of serious adverse reactions of inactive SARS-COV-2 vaccine. Work. 2021;69(3):735-9.","journal-title":"Work"},{"issue":"12","key":"key20221111141118_B23","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3390\/jcm10122629","article-title":"Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey","volume":"10","author":"Riad","year":"2021","unstructured":"Riad A, Sa\u011f\u0131ro\u011flu D, \u00dcst\u00fcn B, Pokorn\u00e1 A, Klugarov\u00e1 J, Attia S, et al. Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey. J Clin Med. 2021;10(12):2629.","journal-title":"J Clin Med"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T19:11:31Z","timestamp":1668193891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/post-vaccination-incidence-and-side-effects-of-covid-19-in-a-cohort-of-brazilian-healthcare-professionals-an-internet-based-survey\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":23,"alternative-id":["10.31744\/einstein_journal\/2022AO0067"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2022ao0067","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"type":"print","value":"1679-4508"},{"type":"electronic","value":"2317-6385"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"eAO0067"}}